Fechtner syndrome is an autosomal dominant disorder which has been thought to be a variant of Alport syndrome. It is characterised by nephritis, sensorineural hearing loss and eye abnormalities, as well as by macrothrombocytopenia and polymorphonuclear inclusion bodies. Recently, the Fechtner syndrome has been mapped in a 5.5 Mb region on the long arm of chromosome 22 by linkage analysis in an extended Israeli family. We describe here the genetic refinement of the Fechtner critical interval to a region less than 600 Kb by linkage analysis performed in a large Italian pedigree. The presence of several recombination events allowed the disease gene to be localised between markers D22S278 and D22S426, in a region containing only two non-recombinant markers, D22S1173 and D22S283. This interval, spanning < 600 Kb on genomic DNA, has been entirely sequenced and contains six known and three putative genes. European Journal of Human Genetics (2000) 8, 895-899.
Introduction
The Fechtner syndrome (FTNS; MIM 153640) is an autosomal dominant disorder first reported by Peterson et al in 1985 . 1 The disorder represents a variant of the well characterised Alport syndrome, 2 since the affected individuals show nephritis, deafness and eye abnormalities together with leukocyte inclusions and macrothrombocytopenia. The inclusion bodies appear similar to toxic Dohle bodies and inclusions observed, under a light microscope, in the MayHegglin anomaly (MHA, MIM 155100), 3, 4 but their ultrastructural appearance is unique. Furthermore, a similar disorder is represented by Epstein syndrome (MIM 153650) which differs from FTNS by the lack of polymorphonuclear inclusion bodies. 5, 6 Finally, Sebastian platelet syndrome is characterised by the same haematological changes present in FTNS but without the manifestations of Alport syndrome. 7, 8 Other families with recurrence of FTNS have been reported. 9, 10 In particular, Gershoni-Baruch et al 9 described a large family in which the affected members showed nephropathy, eye abnormalities, high-tone sensorineural hearing loss, impaired liver functions, hypercholesterolaemia, macrothrombocytopenia and polymorphonuclear inclusion bodies. By a genome-wide search carried out in this family, Toren et al 11 have recently mapped the locus responsible for FTNS syndrome on chromosome 22q11-q13, in a 5.5 Mb interval between markers D22S284 and D22S1167. Interestingly, Kunishima et al, 12 analysing a single Japanese family with MHA, have mapped this disease gene in a 13.6-cM region on chromosome 22q, between D22S280 and D22S272. The MHA locus is completely included in the critical interval defined for FTNS, suggesting the possibility that the two disorders could be due to mutations affecting the same gene. We report here a large family originating from the south of Italy with occurrence of FTNS. In order to refine the critical region of FTNS, we performed linkage studies using a set of highly informative markers from the 22q11-q13 region, spanning the FTNS locus.
Material and methods

Family
In this five-generation family (Figure 1 ) originating from the south of Italy, 10 affected and 15 unaffected individuals were available for the study. Among patients, the phenotype appeared quite variable and segregated in an autosomal Genetic refinement of the Fechtner locus y dominant fashion. All the affected members showed polymorphonuclear inclusion bodies and macrothrombocytopenia. These features, in each patient, were associated in different combinations with high-tone neurosensorial deafness, cataract, abnormal renal function and other features shown in Table 1 . Renal involvement varied from chronic renal failure (III-8 and IV-11 in Figure 1 ) to microscopic haematuria (V-6, V-8 and VI-10 in Figure 1 ). After informed consent obtained by participants, each subject underwent a full physical, ophthalmologic, hearing and haematological evaluation. Haematological studies included a complete blood count and Giemsa staining for the observation of platelet and polymorphonuclear inclusion bodies under a light microscope. Liver and renal function tests and lipid profile were also evaluated.
DNA extraction
Blood samples were obtained from members of the family under informed consent and DNA was extracted using standard protocols.
Genotyping
To refine the critical region for FTNS, the following dinucleotide repeats on 22q11-q13 were typed in the family members: D22S280, D22S281, D22S1158, D22S277, D22S278, D22S1173, D22S283, D22S426, D22S1177, D22S1156, D22S428, D22S284, D22S423. The order of these markers has been physically demonstrated by the sequence of the entire chromosome 22. 13 Primers for markers D22S280, D22S283
and D22S423 were present in the ABI-Prism Linkage Mapping Set Version 2 (ABI, Perkin-Elmer, Norwalk, CT, USA), whilst primers for the remaining markers were synthesised, labelling the forward primer with FAM, TET or HEX fluorescent dyes. PCR was carried out under standard conditions. Amplification products were loaded in an automated sequencer ABI mod 377 (ABI, Perkin-Elmer, Foster City, CA, USA) and allele size defined using the Genescan software.
Linkage analysis
Classic pairwise lod score analysis was carried out in the pedigree using the programs included in the LINKAGE package. 14 The analysis was performed modelling the FTNS as a fully penetrant dominant disorder with an estimated disease allele frequency of 0.001. All the individuals showing at least polymorphonuclear inclusion bodies and macrothrombocytopenia were considered to be affected, since no evidence for a reduced penetrance came out of the analysis of pedigrees already published. Haplotypes reconstruction was performed in order better to characterise the meiotic recombinants and define the critical region for the disease gene. Figure 1 reports the haplotype reconstruction for the chromosome 22q11-q13 markers tested in the family. The maximum lod score values (Z max ) are also shown. In particular, a lod score of 4.10 was obtained for marker D22S283. Several recombination events were detected in the family. In particular, the presence of one recombination event in the healthy individual VI-2 places the FTNS locus proximal to the D22S426 locus. This recombinant defines the telomeric boundary of the FTNS locus between markers D22S426 and D22S283. Furthermore, the affected individuals V-6 and V-8 inherited from the affected mother a recombinant haplotype which shares only the distal part, from marker D22S1173 to D22S423, with the disease haplotype present in the other patients. This recombination event defines the centromeric boundary of the FTNS critical interval between markers D22S278 and D22S1173. Thus, the region containing the FTNS gene is located between markers D22S278 and D22S426 and contains two non-recombinant markers, D22S1173 and D22S283.
Results
Discussion
The results of the present work confirm linkage of FTNS to loci on chromosome 22q11-q13 in a large family originating from the south of Italy. In particular, a lod score of 4.10 at θ = 0.00 was obtained with marker D22S283. The presence of 11 From a genetic point of view, this region spans about 5.6 cM on genomic DNA 15 and includes a minimum of two non-recombinant loci: D22S1173 and D22S283. Interestingly, the MHA has been mapped in the same area by Kunishima et al, 12 in an interval of 13.6 cM located between markers D22S280 and D22S272. These data suggest that the two syndromes, FTNS and MHA, could be allelic and the small region defined by us could contain the gene responsible for these two disorders. These observations are strongly supported by the recent refinement of the MHA locus by Martignetti et al 16 to a 6.6 cM interval between markers D22S683 and D22S1177. Nevertheless, a contiguous gene syndrome could not be excluded. The chromosome 22 is the only human chromosome to has been entirely sequenced. The critical region defined by the recombinants identified in the FTNS family studied is covered by eight overlapping genomic sequences (http:/ /www.sanger.ac.uk/HGP/Chr22) with accession numbers Z82217, Z95114, AL031426, Z82215, AL022302, AL022313, AL031845 and Z70289 respectively, 13 ( Figure 2 ). Based on these data, the size of the FTNS locus is < 600 Kb. In particular, since the proximal recombinant marker D22S278
is localised from bp 67993 to bp 68280 in sequence Z82217 and the distal recombinant marker D22S426 is localised from bp 26234 to bp 26594 in sequence Z70289, we can calculate that the entire critical region for the FTNS locus is 588.053 bp in size, excluding the presence of some small gaps. Several genes have been localised in this interval but have yet to be associated with specific genetic disorders. The apolipoprotein L gene (APOL), the gene encoding for the myosin heavy polypeptide 9 non-muscle (MYH9), the TNFinducible protein CG12-1 mRNA, the eukaryotic translation initiation factor 3 subunit 7 gene (EIF3S7) and the thioredoxin gene (TXN2) are completely included in the FTNS locus, while the calcium channel voltage-dependent gamma subunit 2 gene (CACNG2) is only partially located in the FTNS critical region. In addition, the FNTS locus included a putative APOL2 gene, a sequence matching an EST cluster and a sequence encoding a putative protein similar to human Hermansky-Pudlak syndrome protein as well as several pseudogenes. All the above genes are strong positional candidate for FTNS based on their location within the small critical region identified. Mutational analysis of all these genes is in progress in order to identify the one responsible.
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Figure 2
Schematic representation of the FTNS critical region. All these data are resumed from the sequence of chromosome 22. 13 The white boxes indicate the genomic regions covered by the different genes present in the FTNS locus. The APOL gene is transcribed by the ' + ' strand (cen-tel), whereas MYH9, the TNF-inducible protein CG12-1 mRNA, EIF3S7, TXN2 and CACNG2 by the '-' strand (tel-cen). dJ1119A7.5 and dJ1119A7.3 are putative genes. The CACNG2 gene is only partially located in the FTNS critical region.
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